Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
Holding BMEA?
Track your performance easily
BMEA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.61 - $22.74
Previous Close$8.71
Volume169.07K
Average Volume (3M)818.18K
Market Cap
$311.05M
Enterprise Value$212.45M
Total Cash (Recent Filing)$113.29M
Total Debt (Recent Filing)$10.34M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Oct 29, 2024EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding36,210,167
10 Day Avg. Volume391,697
30 Day Avg. Volume818,182
Standard Deviation0.39
R-Squared0.00378
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$21.00Price Target Upside144.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Biomea Fusion News
Bulls Say, Bears Say
Bulls Say
Market PotentialBMF-219 has shown clinical activity in diabetes (reduction in HbA1c, etc.) and could be complementary to current treatments.
New ProgramBiomea announced that its third program will be a selective GLP-1r agonist focused on obesity, which could take meaningful share in a market expected to be $100B+.
Product DevelopmentBMEA’s lead asset, BMF-219, is a first-in-class irreversible, covalent menin inhibitor, derived from its proprietary FUSION platform.
Bears Say
Clinical TrialsCOV-111 & COV-112 were placed on full clinical holds due to elevated LFT signals observed with higher dosing (400mg) of BMF-219 in the 4-week dose escalation phase of COV-111.
Drug SafetyBiomea's diabetes trials are on clinical hold due to unexpected liver toxicities.
Regulatory IssuesTwo ongoing Phase 1/2 clinical trials evaluating BMF-219 in diabetes were placed on clinical hold by the FDA due to potential signs of drug-induced hepatotoxicity.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $3.61 and its highest was $22.74 in the past 12 months.
What is Biomea Fusion’s market cap?
Currently, no data Available
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Oct 29, 2024 which is in 39 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Jul 31, 2024. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.077 by $0.047.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -$0.96.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 36,210,167 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.077. Following the earnings report the stock price went up 3.232%.
Which hedge fund is a major shareholder of Biomea Fusion?
Among the largest hedge funds holding Biomea Fusion’s share is Baker Bros Advisors LP. It holds Biomea Fusion’s shares valued at 9M.
---
Biomea Fusion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (144.47% Upside)
$21.00 (144.47% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.93%
12-Months-Change
Fundamentals
Return on Equity
-85.09%
Trailing 12-Months
Asset Growth
-45.24%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$21.00
▲(144.47% Upside)
Technical Analysis
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
+1.34%
reiterated a buy rating 2 months ago
Copying George Farmer's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +1.34% per trade.
---